Richard Mularski to Double-Blind Method
This is a "connection" page, showing publications Richard Mularski has written about Double-Blind Method.
Connection Strength
0.229
-
Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. Ann Intern Med. 2022 12; 175(12):1716-1727.
Score: 0.053
-
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial. Lancet Infect Dis. 2023 02; 23(2):233-246.
Score: 0.052
-
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 12; 9(12):1365-1376.
Score: 0.049
-
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 03 04; 384(9):795-807.
Score: 0.046
-
The IBV Valve trial: a multicenter, randomized, double-blind trial of endobronchial therapy for severe emphysema. J Bronchology Interv Pulmonol. 2014 Oct; 21(4):288-97.
Score: 0.030